



Targeted Drugs for Neurodegenerative Diseases Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-27	130	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Targeted Drugs for Neurodegenerative Diseases market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Targeted Drugs for Neurodegenerative Diseases market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Targeted Drugs for Neurodegenerative Diseases market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Targeted Drugs for Neurodegenerative Diseases market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Targeted Drugs for Neurodegenerative Diseases include Eisai Inc., Teva, NOVARTIS, Green Valley, Roche, Lundbeck, Eli Lilly, Biogen and UCB, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Targeted Drugs for Neurodegenerative Diseases market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Targeted Drugs for Neurodegenerative Diseases.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Targeted Drugs for Neurodegenerative Diseases Market by Company

Eisai Inc.

Teva

NOVARTIS

Green Valley

Roche
Lundbeck
Eli Lilly
Biogen
UCB
Supernus Pharmaceuticals
Sumitomo Pharma
Sanofi
Neurocrine
Kyowa Kirin
Janssen
Bristol-Myers Squibb
Acadia Pharmaceuticals Inc.

Targeted Drugs for Neurodegenerative Diseases Segment by Type

Oral
Injection

Targeted Drugs for Neurodegenerative Diseases Segment by Application

Parkinson's Disease (PD)
Huntington's Disease (HD)
Multiple Sclerosis (MS)
Tardive Dyskinesia (TD)
Alzheimer's Disease (AD)

Targeted Drugs for Neurodegenerative Diseases Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Neurodegenerative Diseases market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Neurodegenerative Diseases and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Neurodegenerative Diseases.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Targeted Drugs for Neurodegenerative Diseases companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Targeted Drugs for Neurodegenerative Diseases by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Oral
 - 2.2.3 Injection
- 2.3 Targeted Drugs for Neurodegenerative Diseases by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Parkinson's Disease (PD)
 - 2.3.3 Huntington's Disease (HD)
 - 2.3.4 Multiple Sclerosis (MS)
 - 2.3.5 Tardive Dyskinesia (TD)
 - 2.3.6 Alzheimer's Disease (AD)
- 2.4 Assumptions and Limitations

3 Targeted Drugs for Neurodegenerative Diseases Breakdown Data by Type

- 3.1 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Type (2021-2026)
- 3.2 Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Type (2027-2032)

4 Targeted Drugs for Neurodegenerative Diseases Breakdown Data by Application

- 4.1 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Application (2021-2026)
- 4.2 Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Targeted Drugs for Neurodegenerative Diseases Market Perspective (2021-2032)
- 5.2 Global Targeted Drugs for Neurodegenerative Diseases Growth Trends by Region
 - 5.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Region (2021-2026)
 - 5.2.3 Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Region (2027-2032)
- 5.3 Targeted Drugs for Neurodegenerative Diseases Market Dynamics
 - 5.3.1 Targeted Drugs for Neurodegenerative Diseases Industry Trends
 - 5.3.2 Targeted Drugs for Neurodegenerative Diseases Market Drivers
 - 5.3.3 Targeted Drugs for Neurodegenerative Diseases Market Challenges
 - 5.3.4 Targeted Drugs for Neurodegenerative Diseases Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue

6.1.1 Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue (2021-2026)

6.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2021-2026)

6.2 Global Targeted Drugs for Neurodegenerative Diseases Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Targeted Drugs for Neurodegenerative Diseases Head Office and Area Served

6.4 Global Targeted Drugs for Neurodegenerative Diseases Players, Product Type & Application

6.5 Global Targeted Drugs for Neurodegenerative Diseases Manufacturers Established Date

6.6 Global Targeted Drugs for Neurodegenerative Diseases Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)

7.2 North America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)

7.4 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)

8.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)

8.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)

9.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)

9.4 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

10.1 South America Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)

10.2 South America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032

10.3 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)

10.4 South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032)

10.5 Brazil

10.6 Argentina

10.7 Chile

10.8 Colombia

10.9 Peru

11 Middle East & Africa

11.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size (2021-2032)

11.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032

11.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026)

11.4 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032)

11.5 Saudi Arabia

11.6 Israel

11.7 United Arab Emirates

11.8 Turkey

11.9 Iran

11.10 Egypt

12 Players Profiled

12.1 Eisai Inc.

12.1.1 Eisai Inc. Company Information

12.1.2 Eisai Inc. Business Overview

12.1.3 Eisai Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.1.4 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.1.5 Eisai Inc. Recent Developments

12.2 Teva

12.2.1 Teva Company Information

12.2.2 Teva Business Overview

12.2.3 Teva Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.2.4 Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.2.5 Teva Recent Developments

12.3 NOVARTIS

12.3.1 NOVARTIS Company Information

12.3.2 NOVARTIS Business Overview

12.3.3 NOVARTIS Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.3.4 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.3.5 NOVARTIS Recent Developments

12.4 Green Valley

12.4.1 Green Valley Company Information

12.4.2 Green Valley Business Overview

12.4.3 Green Valley Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.4.4 Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.4.5 Green Valley Recent Developments

12.5 Roche

12.5.1 Roche Company Information

12.5.2 Roche Business Overview

12.5.3 Roche Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.5.4 Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.5.5 Roche Recent Developments

12.6 Lundbeck

12.6.1 Lundbeck Company Information

12.6.2 Lundbeck Business Overview

12.6.3 Lundbeck Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.6.4 Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.6.5 Lundbeck Recent Developments

12.7 Eli Lilly

12.7.1 Eli Lilly Company Information

12.7.2 Eli Lilly Business Overview

12.7.3 Eli Lilly Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.7.4 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.7.5 Eli Lilly Recent Developments

12.8 Biogen

12.8.1 Biogen Company Information

12.8.2 Biogen Business Overview

12.8.3 Biogen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.8.4 Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.8.5 Biogen Recent Developments

12.9 UCB

12.9.1 UCB Company Information

12.9.2 UCB Business Overview

12.9.3 UCB Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.9.4 UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.9.5 UCB Recent Developments

12.10 Supernus Pharmaceuticals

12.10.1 Supernus Pharmaceuticals Company Information

12.10.2 Supernus Pharmaceuticals Business Overview

12.10.3 Supernus Pharmaceuticals Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.10.4 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.10.5 Supernus Pharmaceuticals Recent Developments

12.11 Sumitomo Pharma

12.11.1 Sumitomo Pharma Company Information

12.11.2 Sumitomo Pharma Business Overview

12.11.3 Sumitomo Pharma Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.11.4 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.11.5 Sumitomo Pharma Recent Developments

12.12 Sanofi

12.12.1 Sanofi Company Information

12.12.2 Sanofi Business Overview

12.12.3 Sanofi Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.12.4 Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.12.5 Sanofi Recent Developments

12.13 Neurocrine

12.13.1 Neurocrine Company Information

12.13.2 Neurocrine Business Overview

12.13.3 Neurocrine Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.13.4 Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.13.5 Neurocrine Recent Developments

12.14 Kyowa Kirin

12.14.1 Kyowa Kirin Company Information

12.14.2 Kyowa Kirin Business Overview

12.14.3 Kyowa Kirin Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.14.4 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.14.5 Kyowa Kirin Recent Developments

12.15 Janssen

12.15.1 Janssen Company Information

12.15.2 Janssen Business Overview

12.15.3 Janssen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.15.4 Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.15.5 Janssen Recent Developments

12.16 Bristol-Myers Squibb

12.16.1 Bristol-Myers Squibb Company Information

12.16.2 Bristol-Myers Squibb Business Overview

12.16.3 Bristol-Myers Squibb Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.16.4 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.16.5 Bristol-Myers Squibb Recent Developments

12.17 Acadia Pharmaceuticals Inc.

12.17.1 Acadia Pharmaceuticals Inc. Company Information

12.17.2 Acadia Pharmaceuticals Inc. Business Overview

12.17.3 Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)

12.17.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio

12.17.5 Acadia Pharmaceuticals Inc. Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2021-2026)
- Table 7: Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2027-2032)
- Table 9: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2021-2026)
- Table 11: Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2027-2032)
- Table 13: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2021-2026)
- Table 16: Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2027-2032)
- Table 18: Targeted Drugs for Neurodegenerative Diseases Industry Trends
- Table 19: Targeted Drugs for Neurodegenerative Diseases Industry Drivers
- Table 20: Targeted Drugs for Neurodegenerative Diseases Industry Opportunities and Challenges
- Table 21: Targeted Drugs for Neurodegenerative Diseases Market Restraints
- Table 22: Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2021-2026)
- Table 24: Global Targeted Drugs for Neurodegenerative Diseases Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Headquarters and Area Served
- Table 26: Global Targeted Drugs for Neurodegenerative Diseases Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Targeted Drugs for Neurodegenerative Diseases by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 VS

2025 VS 2032 (US\$ Million)

- Table 43: Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Eisai Inc. Company Information
- Table 46: Eisai Inc. Business Overview
- Table 47: Eisai Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 48: Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 49: Eisai Inc. Recent Developments
- Table 50: Teva Company Information
- Table 51: Teva Business Overview
- Table 52: Teva Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 53: Teva Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 54: Teva Recent Developments
- Table 55: NOVARTIS Company Information
- Table 56: NOVARTIS Business Overview
- Table 57: NOVARTIS Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 58: NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 59: NOVARTIS Recent Developments
- Table 60: Green Valley Company Information
- Table 61: Green Valley Business Overview
- Table 62: Green Valley Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 63: Green Valley Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 64: Green Valley Recent Developments
- Table 65: Roche Company Information
- Table 66: Roche Business Overview
- Table 67: Roche Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 68: Roche Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 69: Roche Recent Developments
- Table 70: Lundbeck Company Information
- Table 71: Lundbeck Business Overview
- Table 72: Lundbeck Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 73: Lundbeck Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 74: Lundbeck Recent Developments
- Table 75: Eli Lilly Company Information
- Table 76: Eli Lilly Business Overview
- Table 77: Eli Lilly Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 78: Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 79: Eli Lilly Recent Developments
- Table 80: Biogen Company Information
- Table 81: Biogen Business Overview
- Table 82: Biogen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 83: Biogen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 84: Biogen Recent Developments
- Table 85: UCB Company Information
- Table 86: UCB Business Overview
- Table 87: UCB Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 88: UCB Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 89: UCB Recent Developments
- Table 90: Supernus Pharmaceuticals Company Information
- Table 91: Supernus Pharmaceuticals Business Overview
- Table 92: Supernus Pharmaceuticals Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 93: Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 94: Supernus Pharmaceuticals Recent Developments
- Table 95: Sumitomo Pharma Company Information
- Table 96: Sumitomo Pharma Business Overview
- Table 97: Sumitomo Pharma Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 98: Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 99: Sumitomo Pharma Recent Developments
- Table 100: Sanofi Company Information
- Table 101: Sanofi Business Overview
- Table 102: Sanofi Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)

- Table 103: Sanofi Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 104: Sanofi Recent Developments
- Table 105: Neurocrine Company Information
- Table 106: Neurocrine Business Overview
- Table 107: Neurocrine Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 108: Neurocrine Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 109: Neurocrine Recent Developments
- Table 110: Kyowa Kirin Company Information
- Table 111: Kyowa Kirin Business Overview
- Table 112: Kyowa Kirin Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 113: Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 114: Kyowa Kirin Recent Developments
- Table 115: Janssen Company Information
- Table 116: Janssen Business Overview
- Table 117: Janssen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 118: Janssen Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 119: Janssen Recent Developments
- Table 120: Bristol-Myers Squibb Company Information
- Table 121: Bristol-Myers Squibb Business Overview
- Table 122: Bristol-Myers Squibb Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 123: Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 124: Bristol-Myers Squibb Recent Developments
- Table 125: Acadia Pharmaceuticals Inc. Company Information
- Table 126: Acadia Pharmaceuticals Inc. Business Overview
- Table 127: Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026) & (US\$ Million)
- Table 128: Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product Portfolio
- Table 129: Acadia Pharmaceuticals Inc. Recent Developments
- Table 130: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Targeted Drugs for Neurodegenerative Diseases Product Image
- Figure 5: Global Targeted Drugs for Neurodegenerative Diseases Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Targeted Drugs for Neurodegenerative Diseases Market Share by Type: 2025 VS 2032
- Figure 7: Oral Product
- Figure 8: Injection Product
- Figure 9: Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 10: Global Targeted Drugs for Neurodegenerative Diseases Market Share by Application: 2025 VS 2032
- Figure 11: Parkinson's Disease (PD) Product
- Figure 12: Huntington's Disease (HD) Product
- Figure 13: Multiple Sclerosis (MS) Product
- Figure 14: Tardive Dyskinesia (TD) Product
- Figure 15: Alzheimer's Disease (AD) Product
- Figure 16: Global Targeted Drugs for Neurodegenerative Diseases Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 17: Global Targeted Drugs for Neurodegenerative Diseases Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 18: Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region: 2025 VS 2032
- Figure 19: Global Targeted Drugs for Neurodegenerative Diseases Market Share by Players in 2025
- Figure 20: Global Targeted Drugs for Neurodegenerative Diseases Manufacturers Established Date
- Figure 21: Global Top 5 and 10 Targeted Drugs for Neurodegenerative Diseases Players Market Share by Revenue in 2025
- Figure 22: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 23: North America Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 24: North America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032)
- Figure 25: United States Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Canada Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 27: Mexico Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032)

- Figure 28: Europe Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: Europe Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032)
- Figure 30: Germany Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: France Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: U.K. Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Italy Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Spain Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Russia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Nordic Countries Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032)
- Figure 40: China Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Japan Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: South Korea Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: India Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032)
- Figure 45: Australia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: China Taiwan Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: South America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021-2032)
- Figure 50: Brazil Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Argentina Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Chile Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Colombia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Peru Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 55: Eisai Inc. Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 56: Teva Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 57: NOVARTIS Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 58: Green Valley Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 59: Roche Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 60: Lundbeck Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 61: Eli Lilly Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 62: Biogen Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 63: UCB Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 64: Supernus Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 65: Sumitomo Pharma Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 66: Sanofi Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 67: Neurocrine Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 68: Kyowa Kirin Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 69: Janssen Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 70: Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)
- Figure 71: Acadia Pharmaceuticals Inc. Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021-2026)